Faricimab demonstrated superior early anatomic outcomes compared to aflibercept in treating neovascular age-related macular degeneration (nAMD), including greater reductions in central subfield thickness and faster resolution of retinal fluid, according to a study.
A pooled analysis of the TENAYA and LUCERNE Phase 3 trials, which enrolled 1,329 treatment-naïve patients aged 50 and older, compared the effects of intravitreal faricimab 6.0 mg (administered every 16 weeks after initial doses) to aflibercept 2.0 mg (administered every 8 weeks after initial doses).
Faricimab produced significantly greater reductions in central subfield thickness at weeks 4, 8, and 12. In addition, a higher proportion of patients treated with faricimab achieved an absence of subretinal fluid (SRF) and both intraretinal and SRF at week 12, with 87.9% versus. 79.0% achieving SRF absence. In terms of fluid resolution, faricimab also showed faster results, with patients reaching the absence of both types of fluid by week 8, compared to week 12 for aflibercept.
Reference
Gemmy Cheung CM, Lim JI, Priglinger S, et al. Anatomic Outcomes With Faricimab vs. Aflibercept in the Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular AMD. Ophthalmology. 2024;S0161-6420(24)00748-6. doi: 10.1016/j.ophtha.2024.11.023. Epub ahead of print. PMID: 39617060.
Related Content
